Navigation Links
New approach to protecting prion protein from altering shape
Date:7/18/2013

A team of researchers from Case Western Reserve University School of Medicine have identified a mechanism that can prevent the normal prion protein from changing its molecular shape into the abnormal form responsible for neurodegenerative diseases. This finding, published in the July 18 issue of Cell Reports, offers new hope in the battle against a foe that until now has always proved fatal.

Prion diseases include Creuzfeldt-Jakob disease and fatal familial insomnia. Unlike other transmissible diseases, the infectious agent is not a virus or bacteria, but an abnormally shaped prion protein. Scientists believe it self-replicates by binding to normal prion proteins and forcing them to change shape to become an abnormal, and thus diseased, protein.

"Once heretical, the notion that proteins alone can act as self-propagating infectious agent is now becoming accepted as a new paradigm in biology and medicine. However, the mechanism by which prion protein changes its shape remains largely unknown and highly controversial, hindering efforts to develop drugs for prion diseases," said Witold Surewicz, PhD, professor of physiology and biophysics and senior author of the study. "A heated debate continues as to which part of the prion protein undergoes the change and what is the three-dimensional structure of the infectious form of the protein."

The researchers generated a variant of prion protein designed to stabilize the normal shape of one specific part of the protein. They accomplished this goal by replacing just one out of more than 200 amino acid residues, the building blocks of the protein. In a series of experiments, the researchers found that the modified prion protein was highly resistant to changing its shape. In other words, this approach may be successful in blocking the coercive action of the abnormal prion protein.

The team then created transgenic mice that produced this "superstable" human prion protein and infected them with Creutzfeldt-Jakob disease prions. The mice did eventually develop symptoms, but the signs did not emerge for more than a year in fact, it took about 400 days. In contrast, mice without the modified prion protein showed symptoms within 260 days.

"Our discovery that a tailor-made mutation in one specific region of prion protein can prevent it from changing shape to a disease-associated conformation helps resolve the ongoing major controversy in the field regarding the mechanism by which infectious prions self-replicate," said Qingzhong Kong, PhD, associate professor of pathology and first author on the paper.

With no effective treatments currently available for these fatal diseases, this finding has also important implications for the development of new drugs. It suggests a novel pharmacologic strategy in which scientists can either identify or design a molecule that binds to prion protein and stabilizes its normal shape, thereby preventing propagation of the disease.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. New data support community-wide approach to addressing child obesity
2. A Future-Proof Approach to Intelligent Buildings
3. New chemical approach to treat Alzheimers
4. Agencies should use common approach to evaluate risks pesticides pose to endangered species
5. Novel therapeutic approaches to cure chronic HBV infection
6. BUSM researchers identify novel approach to study COPD and treatment efficacy
7. Vitamin P as a potential approach for the treatment of damaged motor neurons
8. Einstein study reveals new approach for stopping herpes infections
9. Novel treatment approach for bladder pain using a herpes simplex virus vector reported
10. New approaches for controlling pesticide exposure in children
11. New approach alters malaria maps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: